ArticlemedRxiv : the preprint server for health sciences2025

A phase 2 trial of burosumab for treatment of fibroblast growth factor-23 mediated hypophosphatemia in children and adults with fibrous dysplasia.

Olivia de Jong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.